Kornimate/medical-research-clean huggingface dataset:
the impact of maca supplementation on basketball-related performance

Conditions: Sports

Summary: in this randomized crossover study, ten elite healthy male basketball players were included. following a 17:00 pm training routine, participants completed a two-week supplementation with 2000 mg of maca or placebo. after supplementation, participants underwent a basketball jump shooting accuracy test and repeated sprint ability test.

supplementation with lepidium meyenii (maca) has been shown in animal studies to increase blood lactate clearance and rapid lactate removal, which may be effective in reducing fatigue during intermittent exercise. however, no studies have investigated the effects of maca supplementation on interval exercise and basketball performance. we hypothesized that maca supplementation could reduce fatigue and improve performance in elite healthy male basketball players. this study aimed to determine the effectiveness of maca compared to placebo on overall basketball performance.

Eligibility criteria:
inclusion criteria: * (i) healthy male adults, those individuals who are free of pain, insomnia, or other injuries recently, without any medication used in recent 2 months, * (ii) basketball players competing in a taiwan university basketball association for more than two years. exclusion criteria: * (i) were below 20 years old, * (ii) did not have won at least eighth place in national-level basketball competitions, * (iii) were with cardiovascular diseases or any disease that made subjects feel ill.

Keywords: lepidium meyenii basketball jump shooting accuracy test repeated sprint ability test blood lactate clearance rate ergogenic aids
functional evaluation after breast reconstruction with a minimally invasive latissimus dorsi flap following radical surgery for breast cancer.

Conditions: Breast Cancer

Summary: this study will quantify the muscle function after breast reconstruction using a minimally invasive latissimus dorsi flap. the proposed measures (clinical, isokinetic, electrophysiology, function and quality of life questionnaires) allow a precise, multidisciplinary, objective evaluation of the capacity of the latissimus dorsi muscle before surgery, 3 months, 6 months and 12 months after surgery. a function deficit is expected (decreased moment of adduction and internal rotation) 3 months after surgery and a return to the preoperative state 6 months and 12 months after surgery.


Eligibility criteria:
* inclusion criteria: 1. patient managed for unilateral mr (immediate or secondary) by msld after therapeutic mastectomy. 2. breast assessment (mammography + ultrasound +/- breast mri) normal dating less than 6 months 3. age between 18 and 80 years old 4. signature of free and informed consent * exclusion criteria: 1. patient with metastasis or disease progression 2. patient whose general condition does not allow her to answer a questionnaire or perform physical and functional measurements (neurocognitive disorders and/or neuro-orthopedic disorders) 3. patient with a poor understanding of the french language 4. patient having presented a failure of a first breast reconstruction (failure of diep, prosthesis removal) 5. patient not eligible for mr secondary to cancer (prophylactic mastectomy) or for which the flap was intended to cover loss of substance and not reconstruction 6. patient with a history of contralateral mr (all techniques combined) 7. patient with a history of contralateral breast cancer 8. patient does not have internet access to be able to connect to the "exolis" software

Keywords: breast latissimus dorsi flap
human amniotic versus synthetic membrane as a transient skin cover for pediatric burns

Conditions: Burns

Summary: this is a randomised trial that aims to evaluate whether a transient skin cover made out of human amniotic membranes is effective in managing burns among pediatric patients. the primary outcome of this trial is the proportion of skin grafted amongst participants. secondary outcomes include hospital stay and the number of surgical debridements required by included patients.

patients with burns that compromise 5% or more of total body surface area will be randomised to receive a membrane made out of human amnios or a synthetic cover for the acute phase of care. eligible participants will be children with acute burns (\<24 hours) due to hot liquids that compromise 5% or more of total body surface area. patients with burns due to fire, hot surfaces or chemical agents, those with delayed presentation to the emergency department (\>24 hours), and patients with burns that compromise the head or scalp (exclusively or in cases where this compromise exceeds 50% of the total body surface area affected by the burn). patients whose parents do not authorise participation in this trial will also be excluded. randomisation will be performed by a statistician unaware of the clinical management of included patients. the specific allocation sequence will be kept hidden from other investigators. patients, outcome assessors and statisticians will also be kept unaware of treatment allocation. blinding will be achieved by using image analysis software to assess the primary endpoint. due to the intervention's characteristics, it will be impossible to perform blinding of the attending surgeon. analyses will be performed under the intention - to - treat principle. amniotic membrane samples will be collected by personnel that shall not provide care for included participants. samples suitable for donation will come from elective caesarean sections. once obtained, amniotic membranes will be stored in sterile containers and then sent for irradiation at a facility provided by the comisión chilena de energía nuclear (chilean nuclear energy comission). this sampling protocol includes exclusion of relevant infectious diseases as established by the chilean ministry of health.

Eligibility criteria:
inclusion criteria: * children with an acute burn (\<24 hours) * burn due to hot liquids. * total wound extension at least 5% of total body surface area. exclusion criteria: * burns due to fire, chemical burns or hot surfaces. * delayed burns (\>24 hours). * burns extending solely to the head or scalp. * burns whose compromise of head or scalp is 50% or more of total burn area. * refusal to participate.

Keywords: children skin transplantation amniotic membrane
the impact of jiaji electroacupuncture and scalp electroacupuncture on traumatic spinal cord injury

Conditions: Spinal Cord Injuries (SCI)

Summary: spinal cord injury (sci), leads to functional deficits and complications like neurogenic bladder and deep vein thrombosis, imposing a global annual financial burden. this trial aims to compares jiaji electroacupuncture (jea) and scalp electroacupuncture (sea) in sci rehabilitation. this randomized controlled trial (rct) compared jea and sea in sci rehabilitation.

the motor function score, light touch score, and pinprick sensation score of both groups showed significant improvement ( p \ 0.05), but at week 8 and the 3-month follow-up, the proportion of asia grade improvement in group a was significantly higher than that in group b (week 8: 40.48% vs. 14.29%, p=0.007; 3-month follow-up: 47.62% vs. 21.43%, p = 0.012). at week 4, week 8, and the 3-month follow-up, group a's motor function score, light touch score, pinprick sensation score, and mbi were all higher than those of group b ( p \< 0.05).

Eligibility criteria:
inclusion criteria: 1. the duration of spinal cord injury must be between 3 to 6 months; 2. the site of injury must be clearly defined; 3. the cause of injury must be traumatic; 4. patients must be over 18 years of age; 5. patients must provide consent to participate in this study. exclusion criteria: 1. unknown time or site of injury; 2. disagreement to participate in this study; 3. patients with contraindications for acupuncture intervention (such as skin lesions or rashes at potential acupuncture sites); 4. patients with cognitive or language impairments who are unable to cooperate with scale evaluations.

Keywords: spinal cord injury electroacupuncture jiaji acupoint scalp acupuncture clinical efficacy
cognition, steroids, and imaging in cushings disease

Conditions: Cushing Syndrome

Summary: this study investigates the effects of the glucocorticoid hormone cortisol on brain structure and function. patients with cushing's disease are studied before and after treatment. brain imaging and neuropsychologic tests are used to study changes in the hippocampus and thinking and learning functions as well as mood during the period of elevated cortisol. at several intervals after treatment, these are reexamined to study the degree of reversibility of the abnormalities. the contribution of cortisol as well as testosterone and estrogen to dysfunction and recovery is studied. since elevated cortisol and dysregulation of its secretory system occurs in a significant proportion of the aged and in alzheimers disease and major depressive disorder, these studies will help advance knowledge of the role of cortisol in these conditions.


Eligibility criteria:
inclusion criteria: * patients with suspected cushing's syndrome with clinical findings suggestive of cushing's syndrome and positive screening tests (urinary free cortisol and low dose overnight dexamethasone suppression test). exclusion criteria: none
perioperative bleeding and aspirin use in spine surgery

Conditions: Hemorrhage; Thrombosis

Summary: the investigators would like to further the current understanding of aspirin and its effects on perioperative bleeding by conducting a randomized controlled trial of spinal surgery patients receiving varying doses of aspirin or no aspirin perioperatively. the investigators hypothesize that there will be no significant difference in perioperative blood loss between the different groups.

selected patients will be given either no aspirin, low-dose aspirin (81 mg), or high-dose aspirin (325 mg) in the perioperative period. these dosages are based on the pharmacist's letter/prescriber's letter which provides aspirin dosing recommendations for varying cardiovascular indications. allocation of dosing will be based on computerized randomization in order to achieve approximately 100 patients in each group. patient records will then be assessed for demographic characteristics, comorbidities, symptoms, functional outcome scores (sf-12), operative time, intraoperative estimated blood loss, postoperative blood loss in drainage tubes (when applicable), cumulative blood loss, transfusion of blood products, hemoglobin level, preoperative international normalized ratio (inr), preoperative platelet count, hospital length of stay, and morbidity and mortality including development of nstemi, atrial fibrillation, surgical site infection, pulmonary embolism, and hospital 30-day readmission rates.

Eligibility criteria:
inclusion criteria: * all patients over 18 years old, who are not taking aspirin at the time of operation as part of a current cardiovascular treatment plan, who will undergo spinal surgery from 2016-2019 in the practice of dr. eubanks. exclusion criteria: * any patient under the age of 18 and/or is already taking anticoagulant therapy for an established cardiovascular disease at the time of surgery as part of a cardiovascular therapy.

Keywords: bleeding aspirin spine surgery
evaluation of the antihypertensive effect of hyzaar(r) and cognitive function of hypertensive patients (0954a-322)

Conditions: Hypertension

Summary: evaluate the antihypertensive and neuroprotective effects of hyzaar(r) in elderly subjects in comparison with natrilix(tm).


Eligibility criteria:
inclusion criteria: * acei or arb naive or not taking acei or arb concurrently for at least one month before the run-in period * be able to carry out his or her own daily activity * - be at least 50 years old at inclusion in the study be diagnosed with mild to moderate hypertension, treated or untreated * literate * not taking any cognitive-enhanced agent at baseline * present with a memory complain ( spontaneous or informed by caregiver) exclusion criteria: * congestive heart failure with nyha class \>2 * renal failure or renal insufficiency with serum creatinine \>1.4mg/dl * chronic severe liver disease with abnormal gpt and got \>2 times of upper normal limits * diagnosed with major depression when entering the study * foreign language as his or her mother tongue so that the test results will not be reliable * history of stroke or transient ischemic attack (stroke is defined as focal neurological sign progressing stepwise) * hypersensitive to the active ingredient and any other component of losartan potassium and indapamide tablets * major hearing loss/deafness and/or major visual impairment/blindness preventing from performing the tests * myocardial infarction within the past 6 months * single functioning kidney * anuria
an antibiotic protocol guided by a multimodal approach in aecopd with pneumonia in intensive care

Conditions: To Reduce Duration of Antibiotics Exposure in Patients With COPD Hospitalized in Intensive Care Unit With Pneumonia

Summary: investigators propose to conduct a multicenter, prospective, randomized, controlled, assessing the interests of an antibiotic protocol guided by the combined use of serum procalcitonin (pct) and a broad-panel respiratory multiplex pcr (mpcr) to reduce duration of antibiotics exposure in patients with chronic obstructive pulmonary disease (copd) hospitalized in intensive care unit (icu) with pneumonia. the primary endpoint is the number of antibiotic-days for the treatment of pneumonia.


Eligibility criteria:
inclusion criteria: * patients over 18 years * documented or suspected clinically copd according to the criteria of gold * community-acquired pneumonia defined as the presence of a radiological (i.e., chest x-ray or ctscan) infiltrates consistent with an infectious site and associated with one or more of the following items: dyspnea, cough, sputum, fever above 38 ° c, chest pain, localized crackles with or without signs of pleural effusion, higher leukocytosis at 10,000 / mm³ or leukopenia below 4000 / mm³ * admitted to the hospital for less than 48 hours * icu admission * informed consent signed by the patient or his representative exclusion criteria: * patient immunocompromised including congenital immunodeficiency, haematologic malignancy, immunosuppressive drugs (including anticancer chemotherapy and post-transplantation therapies), neutropenia neutrophil count below 500 / mm³ secondary to chemotherapy, corticosteroids greater than 0.5 mg / kg / day for more than 10 days, hiv infection * therapeutic limitation existence * minor patient or under guardianship or custody * pregnant woman * refusal to participate in the study * the inclusion of the subject in another biomedical research protocol in progress or for less than 30 day * patients treated with antibiotics before icu referral are no excluded.
mtlip vs. itp blocks in lumbar disc surgery

Conditions: Lumbar Disc Herniation; Pain, Postoperative; Regional Aneshesia

Summary: to compare ultrasonography (usg)-guided intertransverse process block and modified thoracolumbar interfascial plan (mtlip) block in the treatment of postoperative pain in patients undergoing lumbar disc herniation surgery under general anesthesia.


Eligibility criteria:
inclusion criteria: * 18-75 years old * asa i-ii-iii risk group * patients whose consent was obtained with an informed consent form * patients who will undergo lumbar disc herniation surgery exclusion criteria: * patients who refused to participate in the study * allergic to local anesthetics * patients with coagulopathy * infection at the site of intervention * patients under 18 years of age * patients with asa score iv and above * chronic pain disorders * those with neurological or neuromuscular disease * patients with psychiatric problems * patients with a history of opioid use * chronic use of nsaids * those contraindicated for regional anesthesia * patients with a history of opioid use * chronic analgesic use

Keywords: postoperative pain opioid consumption pain management nerve blocks qor-15
efficacy and safety of tanzânia association in the treatment of erectile dysfunction associated with benign prostatic hyperplasia

Conditions: Erectile Dysfunction; Benign Prostatic Hyperplasia

Summary: the purpose of this study is to evaluate the efficacy and safety of tanzânia association in adults with erectile dysfunction associated with benign prostatic hyperplasia.


Eligibility criteria:
inclusion criteria: * ability to confirm voluntary participation and agree to all trial purposes by signing and dating the informed consent forms; * male participants aged 18 years or more; * sexually active participants with a defined partner who have averaged 1 attempt at sexual intercourse per week in the past month; * diagnosis of benign prostatic hyperplasia; * diagnosis of erectile dysfunction; * patients with score between 6 and 25 points in the erectile function questionnaire; * ipss (international prostate symptom score) greater or equal to 8 points; exclusion criteria: * known hypersensitivity to the formula components used during the clinical trial; * history of alcohol and/or substance abuse within 2 years; * diagnosis of other diseases or conditions in the urinary tract, including but not limited to: cancer, neurogenic bladder; urinary incontinence, recurrent infection, urethral stricture, bacterial prostatitis; * clinical evidence of prostate cancer; * hypogonadism or absent sexual desire; * severe psychiatric or psychosocial disorders; * primary erectile dysfunction; * polyneuropathy, neurodegenerative diseases, trauma or spinal cord injuries, central nervous system tumors or other conditions that may affect erections; * anatomical penile deformation that can significantly impair erection, including but not limited to: angulation, cavernous fibrosis, peyronie's disease.

Keywords: erectile dysfunction benign prostatic hyperplasia
alterations of gut microbiome, function, and its intervention after defunctioning ileostomy

Conditions: Ileostomy - Stoma; Rectal Cancer; Microbial Disease; Intestinal Functional Disorder

Summary: this study focused on the alterations of gut microbiome and function during defunctioning ileostomy, and observed the effects of probiotic intervention on intestinal microbiome and function. the investigators looked forward to find the specific intestinal maladjusted flora from this work, which could provide a new scheme for the subsequent treatment of the damaged intestinal function and the reduction of the incidence of postoperative complication.


Eligibility criteria:
inclusion criteria: 1. patients with primary rectal cancer received total mesolectal resection combined with defunctioning ileostomy. 2. patients voluntarily sign informed consent. exclusion criteria: 1. disease progression or death after surgery. 2. patients with inflammatory bowl disease. 3. patients need to be on antibiotics/other probiotics for a long time.
pain management for patients with low back pain and psychosocial risk factors in a hospital setting.

Conditions: Low Back Pain

Summary: patients with low back pain and coexisting psychosocial risk factors have a poorer prognosis in terms of quality of life, disability, sick leave and health care use. despite existing literature showing that low back pain patients benefit from cognitive therapy interventions, this has not been investigated in subgroups of low back pain patients with psychosocial risk factors. the purpose of the study is to investigate whether patients referred to secondary care with low back pain and coexisting psychosocial risk factors will have a better treatment outcome when participating in a pain management course in addition to usual care. this will be investigated in a randomised study design, where 130 patients with chronic low back pain and psychosocial risk factors will be randomly allocated to either usual care or a cognitive-therapy based pain management intervention in addition to usual care. the patients will be followed for one year after inclusion, and patientreported outcomes on disability, pain, sick leave, quality of life and pain coping will be collected by the use of questionnaires at baseline, 6 months and 12 months.


Eligibility criteria:
inclusion criteria: * non-specifick low back pain lasting ≥ 3 months * psychosocial risk profile defined as a fear avoidance score \>24 (örebro musculoskeletal pain questionnaire) and/or a bodily distress score \>15 (common mental disorder questionnaire) and/or health anxiety score \>9 (common mental disorder questionnaire) * speaks and understands danish * age ≥ 18 years exclusion criteria: * inflammatory or malignant disease * spine surgery within the last year * untreated or severe depression * psychiatric course of treatment within the last year * abuse of drugs or alcohol * pregnancy

Keywords: low back pain cognitive behavioural therapy randomised controlled trial
safety and efficacy of kovir in the combination regimen with background treatment in covid-19 patients (kovir)

Conditions: COVID-19

Summary: the acute pneumonia pandemic caused by a new strain of corona virus 2019 named as covid-19 by the world health organization (who) is a pandemic caused by sars-cov-2 virus. the reported symptoms vary from fever or chills, cough, shortness of breath, to muscle aches, headaches, loss of taste or smell. the hard capsule kovir is a product based on the traditional medicine named "nhân sâm bài độc táng" which is used to treat the cold conditions, also known as the initial plague according to the theory of traditional medicine.

the acute pneumonia pandemic caused by a new strain of corona virus 2019 named as covid-19 by the world health organization (who) is a pandemic caused by sars-cov-2 virus. the reported symptoms have included, but are not limited to fever or chills, cough, shortness of breath, muscle aches, headaches, loss of taste or smell, diarrhea, dizziness, sore throat, abdominal pain, anorexia, and vomiting. the hard capsule kovir is a product based on the traditional prescription named "nhân sâm bài độc táng" which is used to treat the cold conditions, also known as the initial plague according to the theory of traditional medicine. the study timeline is expected about 7 months, including enrolment period, 14 days of treatment, data entry and analysis. the study compares between standard dose regimen of kovir combined with background treatment in covid-19 patients and placebo combined with background treatment in covid-19 patients. all participants will be treated and followed up in 14-day period. in case the participant meets the discharge criteria before 14 days, discontinuing the study drug will be done at the discretion of the investigators. screening procedures occur at day 1. periodic assessments are conducted daily from day 2-14. finally, end of study visit is conducted.

Eligibility criteria:
inclusion criteria: * male or female, age from 18 to 65 years old, vietnamese nationality * participants diagnosed with positive result of sars-cov-2 using real time rt-pcr test, ct value \ 3log) * voluntary participation in the study by signing an informed consent * ability to adhere to treatment according to the investigator's assessment exclusion criteria: * symptoms of severe upper and lower respiratory tract infections such as dyspnea, spo2\<93%. * acute reduction of ventilation function of respiratory apparatus and/or respiration function of the lung in any of the following three groups: * respiratory distress due to hypoxemia with pao2 less than 60mmhg when breathing room air. * respiratory distress due to hypercapnia with paco2 above 50mmhg * mixed respiratory distress accompanied by both a decrease in pao2 and an increase in paco2 * allergy/intolerance to any component of the study drug. * inability to administer medicine. * severe pneumonia as assessed by the investigator. * inability to comply with study procedures or to ensure compliance with study drug administration as assessed by investigators.